We are live on ! Find out more
OKUR

OnKure Therapeutics
OKUR

42 hedge funds and large institutions have $28.1M invested in OnKure Therapeutics in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 13

9% more capital invested

Capital invested by funds: $25.8M → $28.1M (+$2.34M)

4.48% less ownership

Funds ownership: 84.06% → 79.57% (-4.5%)

14% less funds holding

Funds holding: 49 → 42 (-7)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

88% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 8

Holders
42
Holders Change
-7
Holders Change %
-14.29%
% of All Funds
0.55%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
1
Increased
15
Reduced
13
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SC
Shay Capital
New York
+$337K
2
RC
Rangeley Capital
Connecticut
+$311K
3
PM
Prosight Management
Texas
+$268K
4
Renaissance Technologies
Renaissance Technologies
New York
+$132K
5
GCP
GSA Capital Partners
United Kingdom
+$92.8K

Top Sellers

Rank Fund Capital Flow
1
AAA
Affinity Asset Advisors
New York
-$832K
2
CF
Cantor Fitzgerald
New York
-$440K
3
DTC
Deep Track Capital
Connecticut
-$431K
4
Citadel Advisors
Citadel Advisors
Florida
-$180K
5
TCM
Tang Capital Management
California
-$131K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$26.1K +$4.66K +1,880 +25%
Citigroup
27
Citigroup
New York
$9.14K +$7.61K +3,073 +1,224%
CUAMC
28
China Universal Asset Management Company
China
$6.19K -$805 -325 -13%
TRCT
29
Tower Research Capital (TRC)
New York
$5.32K +$255 +103 +6%
Bank of America
30
Bank of America
North Carolina
$2.46K +$119 +48 +6%
Barclays
31
Barclays
United Kingdom
$1.71K -$929 -375 -38%
Mirae Asset Global Investments
32
Mirae Asset Global Investments
South Korea
$1.37K +$5 +2 +0.4%
JP Morgan Chase
33
JP Morgan Chase
New York
$1.16K +$666 +269 +175%
BNP Paribas Financial Markets
34
BNP Paribas Financial Markets
France
$1K +$77 +31 +9%
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
$1K -$141 -57 -23%
GFM
36
GF Fund Management
China
$745 -$104 -42 -13%
UBS Group
37
UBS Group
Switzerland
$564 +$59 +24 +13%
TCOT
38
Trust Company of Toledo
Ohio
$374 – – –
Osaic Holdings
39
Osaic Holdings
Arizona
$275 – – –
Group One Trading
40
Group One Trading
Illinois
$154 – – –
Fidelity Investments
41
Fidelity Investments
Massachusetts
$138 +$124 +50 New
MCM
42
MAI Capital Management
Ohio
$17 – – –
AAA
43
Affinity Asset Advisors
New York
– -$832K -347,990 Closed
DTC
44
Deep Track Capital
Connecticut
– -$431K -180,510 Closed
NCM
45
Nantahala Capital Management
Connecticut
– -$130K -54,208 Closed
LCM
46
Landscape Capital Management
New Jersey
– -$98.1K -41,051 Closed
Goldman Sachs
47
Goldman Sachs
New York
– -$35.8K -14,964 Closed
B
48
Bailard
California
– -$34K -14,239 Closed
XT
49
XTX Topco
Cayman Islands
– -$25.4K -10,643 Closed
ACM
50
ADAR1 Capital Management
Texas
– -$23.9K -10,000 Closed
1
2

OKUR Hedge Fund Activity: Q3 2025 in Review

42 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q3 2025, worth a combined $28.1M — up 9.1% from $25.8M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of OKUR and 1 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 15 added.

The largest buyer was Shay Capital, adding an estimated $337K. The largest seller was Affinity Asset Advisors, exiting entirely with an estimated $832K sold.

  • 42 institutional investors held OnKure Therapeutics (OKUR) as of Q3 2025, down from 49 in Q2 2025.
  • Funds reported $28.1M of OnKure Therapeutics stock for Q3 2025, up 9.1% quarter-over-quarter.
  • 1 fund opened new OnKure Therapeutics positions in Q3 2025 and 8 closed out, a net change of -7 holders.
  • The largest OnKure Therapeutics buyer in Q3 2025 was Shay Capital, an estimated $337K added.
  • The largest OnKure Therapeutics seller in Q3 2025 was Affinity Asset Advisors, an estimated $832K sold.

Based on aggregated 13F filings for Q3 2025.